Selumetinib - AstraZeneca

Drug Profile

Selumetinib - AstraZeneca

Alternative Names: AR 00142886; AR 142886 X; ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Cincinnati Children's Hospital Medical Center; Merck & Co; National Cancer Centre (Singapore); National Cancer Institute (USA); Netherlands Cancer Institute; University Health Network; University of Cambridge; University of Liverpool
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thyroid cancer
  • Phase II Biliary cancer; Colorectal cancer; Gastrointestinal stromal tumours; Glioma; Histiocytosis; Neurofibromatoses; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Phase I/II Astrocytoma
  • No development reported Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Hepatocellular carcinoma; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Biliary-cancer(Combination therapy, Inoperable/Unresectable, Metastatic disease) in Japan (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease) in United Kingdom (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top